Hepion Pharmaceuticals, Inc.
HEPA
$0.2975
$0.01294.53%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.03% | -25.92% | -25.72% | -18.20% | -7.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.25% | -46.95% | -30.79% | -24.90% | 3.76% |
| Operating Income | 57.25% | 46.95% | 30.79% | 24.90% | -3.76% |
| Income Before Tax | 67.24% | 45.16% | 30.36% | 18.51% | -9.43% |
| Income Tax Expenses | -625.99% | -17.15% | -17.15% | -17.15% | 85.82% |
| Earnings from Continuing Operations | 73.04% | 49.18% | 33.57% | 20.63% | -15.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.04% | 49.18% | 33.57% | 20.63% | -15.94% |
| EBIT | 57.25% | 46.95% | 30.79% | 24.90% | -3.76% |
| EBITDA | 57.26% | 46.96% | 30.81% | 24.95% | -3.79% |
| EPS Basic | 82.39% | 64.25% | 45.95% | 29.96% | -4.34% |
| Normalized Basic EPS | 64.64% | 57.17% | 38.07% | 25.83% | -1.22% |
| EPS Diluted | 82.39% | 64.25% | 45.95% | 29.96% | -4.34% |
| Normalized Diluted EPS | 64.64% | 57.17% | 38.07% | 25.83% | -1.22% |
| Average Basic Shares Outstanding | 54.66% | 43.93% | 25.34% | 12.50% | 4.20% |
| Average Diluted Shares Outstanding | 54.66% | 43.93% | 25.34% | 12.50% | 4.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |